DSpace@İnönü

Use of biphasic ınsulin aspart 30 in type 2 diabetes treatment: expert panelrecommendations

Basit öğe kaydını göster

dc.contributor.author Şahin, İbrahim
dc.date.accessioned 2019-07-30T12:48:30Z
dc.date.available 2019-07-30T12:48:30Z
dc.date.issued 2018
dc.identifier.citation Şahin, İ. (2018). Use of biphasic ınsulin aspart 30 in type 2 diabetes treatment: expert panelrecommendations. Cilt:22 Sayı:3, 183-197 ss. tr_TR
dc.identifier.uri http://hdl.handle.net/11616/13099
dc.description.abstract The goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin insufficiency and/or insulin resistance, delay beta cell damage/depletion, and prevent other metabolic co-morbidities and complications. In the current treatment algorithms, lifestyle changes (medical nutrition therapy, physical exercise) and oral anti-diabetics are followed by insulin therapy, which is considered a replacement therapy for Type 2 diabetes. Pre-mixed insulin preparations, which are an option for patients with poor blood glucose level control under oral anti-diabetics treatment, have been developed to meet both basal and prandial insulin needs by simulating the physiological changes in insulin levels. The consensus on the necessity of individualizing insulin therapy requires physicians to have a detailed knowledge of the various uses of insulin. Therefore, this comprehensive consensus statement has been prepared by a panel of expert endocrinologists from different regions of Turkey to help physicians use biphasic insulin aspart 30 in suitable patients at the right time. In this statement, expert panel opinions on (a) Recommendations for the appropriate initiation, titration, and intensification of insulin treatment, and (b) The treatment algorithms in initiation, titration, and intensification of biphasic insulin aspart 30 treatment and special conditions specific to changing treatment regimen are presented. tr_TR
dc.language.iso eng tr_TR
dc.publisher Galenos yayıncılık, erkan mor, molla guranı cad 21-1, fındıkzade, ıstanbul 34093, turkey tr_TR
dc.relation.isversionof 10.25179/tjem.2017-57420 tr_TR
dc.rights info:eu-repo/semantics/openAccess tr_TR
dc.subject Postprandıal Plasma-Glucose tr_TR
dc.subject Pancreatıc-Cancer tr_TR
dc.subject Glycemıc Control tr_TR
dc.subject Clınıcal Endocrınologısts tr_TR
dc.subject Cardıovascular Events tr_TR
dc.subject Amerıcan Assocıatıon tr_TR
dc.subject Premıxed Formulatıon tr_TR
dc.subject Independent Rısk tr_TR
dc.subject Humalog Mıx25 tr_TR
dc.subject Blood-Glucose tr_TR
dc.title Use of biphasic ınsulin aspart 30 in type 2 diabetes treatment: expert panelrecommendations tr_TR
dc.type article tr_TR
dc.relation.journal Turkısh journal of endocrınology and metabolısm tr_TR
dc.contributor.department İnönü Üniversitesi tr_TR
dc.identifier.volume 22 tr_TR
dc.identifier.issue 3 tr_TR
dc.identifier.startpage 183 tr_TR
dc.identifier.endpage 197 tr_TR


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster